Dr. Barakat's research is focused on examining risk-and-resilience models to characterize disease management and health-related quality of life of children with chronic health conditions and their families. Another focus of investigation is translation of these models into evidence-based assessment (family psychosocial risk screening) as well as family-based, mHealth interventions to improve disease management and to support medical decision-making for youth with cancer and their families.
New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders—complex conditions with severe energy deficiency for which no proven effective treatments exist. Future clinical research is needed to explore whether the drug, cysteamine bitartrate, will meaningfully benefit patients.
What's going on inside our bodies and brains when we respond to stress? Previously, we covered research into powerful little neuropeptides called orexins that may help regulate an individual's vulnerability to stress.